| Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Wei Yang, Ken-Wing Lee, Raghvendra M. Srivastava Nature Medicine 25, 767–775, 2019 | 322 | 2019 |
| P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer LM Dillon, JR Bean, W Yang, K Shee, LK Symonds, JM Balko, ... Oncogene 34 (30), 3968-3976, 2015 | 86 | 2015 |
| Therapeutically targeting tumor microenvironment–mediated drug resistance in estrogen receptor–positive breast cancer K Shee, W Yang, JW Hinds, RA Hampsch, FS Varn, NA Traphagen, ... Journal of Experimental Medicine 215 (3), 895-910, 2018 | 70 | 2018 |
| Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells H Zhu, W Yang, L He, W Ding, L Zheng, S Liao, P Huang, W Lu, Q He, ... PloS one 7 (12), e52333, 2012 | 59 | 2012 |
| Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity X Ma, N Riaz, RM Samstein, M Lee, V Makarov, C Valero, D Chowell, ... Nature genetics 54 (7), 996-1012, 2022 | 42 | 2022 |
| GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1 L Zheng, W Yang, C Zhang, W Ding, H Zhu, N Lin, H Wu, Q He, B Yang Cancer letters 309 (1), 27-36, 2011 | 42 | 2011 |
| Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha–Positive, PIK3CA-Mutant Breast Cancer W Yang, SR Hosford, LM Dillon, K Shee, SC Liu, JR Bean, L Salphati, ... Clinical Cancer Research 22 (9), 2250-2260, 2016 | 36 | 2016 |
| Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen A Poole, V Karuppiah, A Hartt, JN Haidar, S Moureau, T Dobrzycki, ... Nature communications 13 (1), 5333, 2022 | 35 | 2022 |
| Combined inhibition of both p110α and p110β isoforms of phosphatidylinositol 3-kinase is required for sustained therapeutic effect in PTEN-deficient, ER+ breast cancer SR Hosford, LM Dillon, SJ Bouley, R Rosati, W Yang, VS Chen, ... Clinical Cancer Research 23 (11), 2795-2805, 2017 | 31 | 2017 |
| Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor–positive breast cancer W Yang, SR Hosford, NA Traphagen, K Shee, E Demidenko, S Liu, ... The FASEB Journal 32 (3), 1222, 2018 | 27 | 2018 |
| Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer W Yang, GN Schwartz, JD Marotti, V Chen, NA Traphagen, J Gui, ... Oncotarget 9 (10), 8810, 2018 | 21 | 2018 |
| The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer JR Bean, SR Hosford, LK Symonds, P Owens, LM Dillon, W Yang, K Shee, ... Breast cancer research and treatment 149, 69-79, 2015 | 17 | 2015 |
| Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium Jingming Wang, Maximilian Linxweiler, Wei Yang, Timothy Chan, Luc Morris Oncotarget 10, 3835-3839, 2019 | 11 | 2019 |
| Nutlin-1 strengthened anti-proliferation and differentiation-inducing activity of ATRA in ATRA-treated p-glycoprotein deregulated human myelocytic leukemia cells L Zhang, Y Yan, D Zhu, W Yang, W Wang, Y Hu, B Yang, Q He Investigational new drugs 30, 37-47, 2012 | 10 | 2012 |
| A transcriptionally definable subgroup of triple-negative breast and ovarian cancer samples shows sensitivity to HSP90 inhibition K Shee, JD Wells, M Ung, RA Hampsch, NA Traphagen, W Yang, SC Liu, ... Clinical Cancer Research 26 (1), 159-170, 2020 | 3 | 2020 |
| Bleeding with concomitant ibrutinib and oral anticoagulant therapy: A population-based cohort study N Dhopeshwarkar, W Yang, S Hennessy, JM Rhodes, A Cuker, ... American journal of hematology 98 (3), E49, 2023 | 1 | 2023 |
| Panel-based estimates of tumor mutational burden: characterizing unknown unknowns W Yang, LGT Morris, TA Chan Annals of Oncology 30 (9), 1413-1415, 2019 | 1 | 2019 |
| Abstract PD4-08: a microenvironment secretome screen reveals FGF2 as a mediator of resistance to anti-estrogens and PI3K/mTOR pathway inhibitors in ER+ breast cancer K Shee, JW Hinds, W Yang, RA Hampsch, K Patel, FS Varn, C Cheng, ... Cancer Research 78 (4_Supplement), PD4-08-PD4-08, 2018 | 1 | 2018 |
| A microenvironment secretome screen reveals FGF2 as a mediator of resistance to anti-estrogens and PI3K/mTOR pathway inhibitors in ER plus breast cancer K Shee, JW Hinds, W Yang, RA Hampsch, K Patel, FS Varn, C Cheng, ... Cancer Research 78 (4), 2018 | 1 | 2018 |
| Combining Super Learner with high‐dimensional propensity score to improve confounding adjustment: A real‐world application in chronic lymphocytic leukemia N Dhopeshwarkar, W Yang, S Hennessy, JM Rhodes, A Cuker, ... Pharmacoepidemiology and Drug Safety 33 (1), e5678, 2024 | | 2024 |
